Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
new york blog main
new york top stories
9
×
san francisco blog main
9
×
san francisco top stories
national top stories
raleigh-durham blog main
raleigh-durham top stories
biotech
boston blog main
boston top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
amgen
cancer
merck
purdue pharma
bristol-myers squibb
cholesterol
diagnostics
europe blog main
europe top stories
fda
glaxosmithkline
hepatitis b
What
drug
9
×
bio
pricing
roundup
cancer
ceo
cholesterol
fda
immunotherapy
lowering
market
medicine
new
patients
plan
week
aces
acquisitions
activity
advanced
advantages
agency
aimmune
allergy
anathema
announced
approval
approved
arrival
awaited
award
awarded
bar
big
biggest
biotech
brings
build
buy
companies
Language
unset
9
×
Current search:
drug
×
unset
×
" san francisco blog main "
×
" new york top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs